Key facts
- Our Dutch head office is located in Utrecht
- BMS has been active in the Netherlands for more than 50 years
- In 2024 BMS wil open its first European CAR T facility in the Leiden Bio Science Park
- Every day our people work together to save the lives of patients with solid and blood cancers, heart disease and autoimmune diseases
- Through more than 100 active clinical trials, we ensure that Dutch patients have access to the most promising new medicines
We continue to invest and develop our pipeline, and we are the leader in a number of new indications.
BMS worldwide
Update 2021
Chief Executive Officer:
Headquarters:
New York City
Business:
Biopharmaceuticals
Website:
NYSE Listing:
BMY
Net Global Sales:
$42.5 billion in 2020
R&D Investment:
$11.14 billion which included the discovery and development of new medicines for patients
Principal Locations:
BMS in the Netherlands
Update 2021
General Manager:
Sally Ann McNab
Local Headquarters:
Orteliuslaan 1000
3528 BD Utrecht
Key Therapeutic Areas:
Oncology
Hematology
Cardiovascular
Immunology